Andrew Hindman
Director/Board Member chez BIOTIE THERAPIES CORP
Fortune : 3 M $ au 31/03/2024
Postes actifs de Andrew Hindman
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOTIE THERAPIES CORP | Director/Board Member | 01/12/2016 | - |
Historique de carrière de Andrew Hindman
Anciens postes connus de Andrew Hindman
Sociétés | Poste | Début | Fin |
---|---|---|---|
THERAVANCE BIOPHARMA, INC. | Director of Finance/CFO | 04/06/2019 | 31/12/2022 |
ACORDA THERAPEUTICS, INC. | Corporate Officer/Principal | 04/10/2016 | 31/05/2019 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Director/Board Member | 05/04/2011 | 01/01/2014 |
Chief Executive Officer | 06/04/2011 | 01/01/2014 | |
President | 06/04/2011 | 01/01/2014 | |
Nodality, Inc.
Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/05/2010 | 01/01/2011 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/1998 | 01/01/2008 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01/08/2008 | - |
Head of Private Banking | 01/08/2008 | 04/01/2011 |
Formation de Andrew Hindman
The Trustees of Columbia University in The City of New York | Masters Business Admin |
Wesleyan University | Undergraduate Degree |
Haas School of Business | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 10 |
Finlande | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Masters Business Admin | 2 |
Director/Board Member | 2 |
Sectorielle
Health Technology | 8 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
ACORDA THERAPEUTICS, INC. | Health Technology |
THERAVANCE BIOPHARMA, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Nodality, Inc.
Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | Health Technology |
Biotie Therapies Oy
Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Andrew Hindman
- Expérience